Cyclosporine C2 Target Levels and Acute Cellular Rejection After Lung Transplantation
Authors:
- Allan R. GlanvilleAGAllan R. Glanville
- Christina L. AboyounCAChristina L. Aboyoun
- Judith M. MortonJMJudith M. Morton
- Marshall PlitMPMarshall Plit
- Monique A. MaloufMMMonique A. Malouf
- 1 August 2006
- journal article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 25 (8) , 928-934
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Monitoring C2 Level Predicts Exposure in Maintenance Lung Transplant Patients Receiving the Microemulsion Formulation of Cyclosporine (Neoral)The Journal of Heart and Lung Transplantation, 2005
- Use of Neoral C2 monitoring: a European consensusTransplant International, 2005
- Association of Minimal Rejection in Lung Transplant Recipients with Obliterative BronchiolitisAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Cyclosporine C2 monitoring is superior to C0 in predicting acute cellular rejection in heart transplant recipients in TaiwanTransplantation Proceedings, 2004
- Patient management by cyclosporine C2 monitoringTransplantation, 2004
- Sampling Strategy to Calculate the Cyclosporin‐A Area Under the Time‐Concentration CurveAmerican Journal of Transplantation, 2002
- Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteriaThe Journal of Heart and Lung Transplantation, 2002
- Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2)1Transplantation, 2002
- Cyclosporine Microemulsion (Neoral®) Absorption Profiling and Sparse-sample Predictors During the First 3 Months after Renal TransplantationAmerican Journal of Transplantation, 2002
- Therapeutic whole-blood levels of cyclosporin A in heart and lung transplantationClinica Chimica Acta, 1994